Skip to main content
. Author manuscript; available in PMC: 2018 Jul 21.
Published in final edited form as: ACS Chem Biol. 2017 Jun 7;12(7):1883–1892. doi: 10.1021/acschembio.7b00147

Figure 1. Single agent cellular anticancer activity of AZD1775 in NSCLC cells.

Figure 1

(A) Dose-response curves for cell viability effects of 72 h AZD1775 treatment on H322, A427, H1155 and H1648 NSCLC cells and IC50 values for inhibition of viability. (B) Immunoblot analysis of untreated H322 and H1648 cells for WEE1, CDK1 and pY15 CDK1. (C) Immunoblot analysis of γH2AX and total H2AX in H322 and H1648 cells upon 4 h AZD1775 (1 μM) or cisplatin (14 μM) treatment. Arrows indicate un-ubiquitinated (~16 kDa) and mono-ubiquitinated (~25 kDa) γH2AX. (D) Immunoblot analysis of PARP1 and caspase 3 cleavage in H322 and H1648 cells treated with indicated concentrations of AZD1775 or 100 nM staurosporine (STS) for 48 h.